Richard Daly - CEO, Catalyst Pharmaceuticals - Novel Medicines For Patients With Rare Diseases episode artwork

EPISODE · Nov 24, 2025 · 35 MIN

Richard Daly - CEO, Catalyst Pharmaceuticals - Novel Medicines For Patients With Rare Diseases

from Progress, Potential, and Possibilities Podcast / Show · host Ira Pastor / Richard Daly

Send us Fan MailRichard Daly is President and Chief Executive Officer of Catalyst Pharmaceuticals ( https://catalystpharma.com/ ), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases.Catalyst has successfully brought three therapies to market: FIRDAPSE ( https://firdapse.com/ ) for Lambert Eaton Myasthenic Syndrome (LEMS), AGAMREE ( https://agamree.com/ ) for Duchenne Muscular Dystrophy (DMD), and FYCOMPA ( https://www.fycompa.com/ ) for epilepsy.Prior to joining Catalyst, Mr. Daly served as President of CARsgen Therapeutics Corporation, an emerging oncology company focused on developing CAR-T therapies for both liquid and solid tumors, and as Chief Operating Officer of BeyondSpring Pharmaceuticals, a pre-commercial biotech company focused on oncology with assets in late Phase 3 clinical trials. Before joining BeyondSpring, Mr. Daly served as Chairman and CEO of Neuralstem, Inc., a biopharmaceutical company focused on the development of central nervous system therapies based on its neuronal stem cell technology; as a partner of RavineRock Partners, a commercial consulting practice focused on biotech and pharmaceuticals; and as President of AstraZeneca US Diabetes. Mr. Daly also has served on the board of directors of Opiant Pharmaceuticals and Synergy Pharmaceuticals.Mr. Daly received his Bachelor of Science in Microbiology from the University of Notre Dame and his MBA from the Kellogg School of Management, Northwestern University.#RichardDaly #CatalystPharmaceuticals #RareDiseases #OrphanDiseases #FIRDAPSE #LambertEatonMyasthenicSyndrome #AGAMREE #DuchenneMuscularDystrophy #FYCOMPA #Epilepsy #PotassiumChannelBlocker #VoltageGatedCalciumChannels #Dystrophin #NextGenerationSteroid #DissociativeSteroid #GlucocorticoidReceptor #AMPAReceptorAntagonist #Glutamate #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Episode metadata supplied by the publisher feed · Published Nov 24, 2025

Embed this episode

Send us Fan Mail Richard Daly is President and Chief Executive Officer of Catalyst Pharmaceuticals ( https://catalystpharma.com/ ), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. Catalyst has successfully brought three therapies to market: FIRDAPSE ( https://firdapse.com/ ) for Lambert Eaton Myasthenic Syndrome (LEMS), AGAMREE ( https://agamree.com/ ) for Duchenne Muscular Dystrophy...

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

Richard Daly - CEO, Catalyst Pharmaceuticals - Novel Medicines For Patients With Rare Diseases

0:00 35:51

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Progress, Potential, and Possibilities Podcast / Show?

This episode is 35 minutes long.

When was this Progress, Potential, and Possibilities Podcast / Show episode published?

This episode was published on November 24, 2025.

Can I download this Progress, Potential, and Possibilities Podcast / Show episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!